OCID 2987

Drug Profile

OCID 2987

Latest Information Update: 22 Dec 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Orchid Chemicals & Pharmaceuticals
  • Class Anti-inflammatories; Antiasthmatics; Bronchodilators; Eye disorder therapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Asthma; Atopic dermatitis; Chronic obstructive pulmonary disease; Uveitis

Most Recent Events

  • 13 Sep 2014 No development reported - Phase-I for Asthma (In volunteers) in Netherlands (PO)
  • 13 Sep 2014 No development reported - Phase-I for Chronic obstructive pulmonary disease (In volunteers) in Netherlands (PO)
  • 13 Sep 2014 No development reported - Preclinical for Atopic dermatitis in India (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top